BACKGROUND: Danazol is a drug most widely used for the prophylaxis of hereditary angioedema resulting from the deficiency of the C1-inhibitor. Potential hepatotoxic or liver tumor-inducing side effects of long-term danazol prophylaxis have been investigated during the follow-up of hereditary angioedema patients. METHODS: Characteristic parameters of liver function (including bilirubin, GOT, GPT, gammaGT, total protein, ALP, LDH), as well as findings of viral serology screens and abdominal ultrasonography-determined during years 0 and 5 of follow-up of patient groups taking/not taking danazol-have been reviewed and analyzed comparatively. RESULTS: From a population of 126 hereditary angioedema patients, 46 subjects taking danazol and another 46 not taking danazol fulfilled the inclusion criteria. Longitudinal follow-up did not reveal any clinically relevant difference between the liver function parameters determined in years 0 and 5 in the two groups. Abdominal ultrasound did not detect neoplastic or other potentially treatment-related alterations of the liver parenchyma. There were no discontinuations of treatment during the study. CONCLUSIONS: Our results clearly suggest that, administered at the lowest effective dose, danazol does not induce liver injury in hereditary angioedema patients.
BACKGROUND:Danazol is a drug most widely used for the prophylaxis of hereditary angioedema resulting from the deficiency of the C1-inhibitor. Potential hepatotoxic or liver tumor-inducing side effects of long-term danazol prophylaxis have been investigated during the follow-up of hereditary angioedemapatients. METHODS: Characteristic parameters of liver function (including bilirubin, GOT, GPT, gammaGT, total protein, ALP, LDH), as well as findings of viral serology screens and abdominal ultrasonography-determined during years 0 and 5 of follow-up of patient groups taking/not taking danazol-have been reviewed and analyzed comparatively. RESULTS: From a population of 126 hereditary angioedemapatients, 46 subjects taking danazol and another 46 not taking danazol fulfilled the inclusion criteria. Longitudinal follow-up did not reveal any clinically relevant difference between the liver function parameters determined in years 0 and 5 in the two groups. Abdominal ultrasound did not detect neoplastic or other potentially treatment-related alterations of the liver parenchyma. There were no discontinuations of treatment during the study. CONCLUSIONS: Our results clearly suggest that, administered at the lowest effective dose, danazol does not induce liver injury in hereditary angioedemapatients.
Authors: M Cicardi; L Bergamaschini; A Tucci; A Agostoni; G Tornaghi; G Coggi; R Colombi; G Viale Journal: J Allergy Clin Immunol Date: 1983-09 Impact factor: 10.793
Authors: Pedro Giavina-Bianchi; Alfeu T França; Anete S Grumach; Abílio A Motta; Fátima R Fernandes; Regis A Campos; Solange O Valle; Nelson A Rosário; Dirceu Sole Journal: Clinics (Sao Paulo) Date: 2011 Impact factor: 2.365
Authors: Marcus Maurer; Markus Magerl; Stephen Betschel; Werner Aberer; Ignacio J Ansotegui; Emel Aygören-Pürsün; Aleena Banerji; Noémi-Anna Bara; Isabelle Boccon-Gibod; Konrad Bork; Laurence Bouillet; Henrik Balle Boysen; Nicholas Brodszki; Paula J Busse; Anette Bygum; Teresa Caballero; Mauro Cancian; Anthony J Castaldo; Danny M Cohn; Dorottya Csuka; Henriette Farkas; Mark Gompels; Richard Gower; Anete S Grumach; Guillermo Guidos-Fogelbach; Michihiro Hide; Hye-Ryun Kang; Allen P Kaplan; Constance H Katelaris; Sorena Kiani-Alikhan; Wei-Te Lei; Richard F Lockey; Hilary Longhurst; William Lumry; Andrew MacGinnitie; Alejandro Malbran; Inmaculada Martinez Saguer; Juan José Matta Campos; Alexander Nast; Dinh Nguyen; Sandra A Nieto-Martinez; Ruby Pawankar; Jonathan Peter; Grzegorz Porebski; Nieves Prior; Avner Reshef; Marc Riedl; Bruce Ritchie; Farrukh Rafique Sheikh; William B Smith; Peter J Spaeth; Marcin Stobiecki; Elias Toubi; Lilian Agnes Varga; Karsten Weller; Andrea Zanichelli; Yuxiang Zhi; Bruce Zuraw; Timothy Craig Journal: World Allergy Organ J Date: 2022-04-07 Impact factor: 5.516
Authors: Stephen Betschel; Jacquie Badiou; Karen Binkley; Jacques Hébert; Amin Kanani; Paul Keith; Gina Lacuesta; Bill Yang; Emel Aygören-Pürsün; Jonathan Bernstein; Konrad Bork; Teresa Caballero; Marco Cicardi; Timothy Craig; Henriette Farkas; Hilary Longhurst; Bruce Zuraw; Henrik Boysen; Rozita Borici-Mazi; Tom Bowen; Karen Dallas; John Dean; Kelly Lang-Robertson; Benoît Laramée; Eric Leith; Sean Mace; Christine McCusker; Bill Moote; Man-Chiu Poon; Bruce Ritchie; Donald Stark; Gordon Sussman; Susan Waserman Journal: Allergy Asthma Clin Immunol Date: 2014-10-24 Impact factor: 3.406
Authors: Timothy Craig; Emel Aygören-Pürsün; Konrad Bork; Tom Bowen; Henrik Boysen; Henriette Farkas; Anete Grumach; Constance H Katelaris; Richard Lockey; Hilary Longhurst; William Lumry; Markus Magerl; Immaculada Martinez-Saguer; Bruce Ritchie; Alexander Nast; Ruby Pawankar; Bruce Zuraw; Marcus Maurer Journal: World Allergy Organ J Date: 2012-12 Impact factor: 4.084
Authors: Richard G Gower; Paula J Busse; Emel Aygören-Pürsün; Amin J Barakat; Teresa Caballero; Mark Davis-Lorton; Henriette Farkas; David S Hurewitz; Joshua S Jacobs; Douglas T Johnston; William Lumry; Marcus Maurer Journal: World Allergy Organ J Date: 2011-02 Impact factor: 4.084